On Thursday, Shares of HCA Holdings, Inc. (NYSE:HCA), declined -5.01% to $72.21.
HCA Holdings, declared preliminary financial and operating results for its third quarter ended September 30, 2015. The financial results are subject to finalization of the Company’s quarterly financial and accounting procedures.
HCA anticipates revenues for the third quarter of 2015 should approximate $9.856 billion contrast to $9.220 billion in the third quarter of 2014. Income before income taxes for the third quarter is predictable to approximate $921 million contrast to $929 million in the prior year period. Net income per diluted share for the third quarter of 2015 is predictable to be about $1.17 per diluted share contrast to $1.16 per diluted share for the third quarter of 2014. Adjusted EBITDA for the third quarter of 2015 is predictable to be about $1.815 billion contrast to $1.828 billion in the previous year’s third quarter. Adjusted EBITDA is a non-GAAP financial measure.
Operating margins declined in the quarter as a result of raised labor costs and a less favorable payer mix. Labor costs raised as a percent of revenues to 46.9 percent contrast to 45.7 percent in last year’s third quarter. This improvement was driven primarily by less productivity and a greater use of contract labor to fill staffing needs.
The third quarter 2015 results are predictable to comprise losses on sales of facilities of about $2 million. The third quarter 2014 results comprised losses on sales of facilities of $12 million, or $0.02 per diluted share.
HCA Holdings, Inc., through its auxiliaries, provides health care services in the United States. It operates general, acute care hospitals that offer medical and surgical services, counting inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
On other hand, Merck & Co. Inc. (NYSE:MRK), is down -4.34% over 12 months and trades at 13.41 times forward earnings. The consensus price target is $63.47. The Company recently closed at $50.72, up 2.38%. The company has a market cap of $142.86B. The P/E ratio is 14.83. its dividend payout ratio is 51.40%. Its next earning is expected on October 27 before the market open.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
